Indications for allogeneic and autologous haematopoietic cell transplantations in the Czech Republic in 2016: Recommendations of the Transplant Section of the Czech Society of Haematology and the Czech Society of Oncology of the J. E. Purkyně Medical Association
Abstract
Haematopoietic cell transplantation (HCT) remains at present (2016) a very important and irreplaceable treatment option. The main indications for HCT are haematological malignancies (90% of all indications), non-malignant disorders (6%) and solid tumours (4%).
The last recommendations for HCT indications were published by the Czech Society of Haematology and the Czech Society of Oncology in 2006. An up-to-dated version of the previous report has been prepared by the authors on behalf of both professional societies in 2016.
Recommendations presented in this article are mainly based on the current practise of European transplant centres and on recommendations published by the European Group for Blood and Marrow Transplantation (EBMT) in 2015. The aim of this report is to provide an up to date guide to hospitals not directly involved in haematopoietic cell transplantations regarding the correct and well-timed indication of HCT.
This article also aims to provide other specialist information relating to HCT.